Currently, there are 46.89M common shares owned by the public and among those 46.30M shares have been available to trade.
The company’s stock has a 5-day price change of -2.79% and -24.30% over the past three months. RNLX shares are trading -19.49% year to date (YTD), with the 12-month market performance down to -89.74% lower. It has a 12-month low price of $0.22 and touched a high of $3.14 over the same period. RNLX has an average intraday trading volume of 1.94 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.52%, -7.86%, and -42.43% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Renalytix Plc ADR (NASDAQ: RNLX) shares accounts for 9.17% of the company’s 46.89M shares outstanding.
It has a market capitalization of $26.05M and a beta (3y monthly) value of 2.78. The earnings-per-share (ttm) stands at -$0.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.77% over the week and 13.56% over the month.
Earnings per share for the fiscal year are expected to increase by 12.87%, and 26.63% over the next financial year.
Looking at the support for the RNLX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 18, 2022, with the firm’s price target at $30. BTIG Research coverage for the Renalytix Plc ADR (RNLX) stock in a research note released on January 04, 2022 offered a Buy rating with a price target of $24. Guggenheim was of a view on October 04, 2021 that the stock is Buy, while Berenberg gave the stock Buy rating on July 02, 2021, issuing a price target of $38. Stifel on their part issued Buy rating on August 11, 2020.
